title: Short-term effects of testolactone compared to other treatment modalities on longitudinal growth and ovarian activity in a girl with McCune-Albright syndrome.
abstract: In a 6 1/2-month-old girl with McCune-Albright syndrome, gonadotropin-independent isosexual precocity and recurrent ovarian cysts, the short-term effects of surgical therapy, cyproterone acetate (120 mg/m2/d), combined medroxyprogesterone acetate (10 mg/d), and spironolactone (50-75 mg/d) treatment, and testolactone (40 mg/kg/d) were evaluated sequentially. No significant reduction of cyst frequency was achieved with any of the medical treatments. The rate of bone maturation (delta BA/delta CA) was increased and the height standard deviation score (SDS) for bone age as a potential indicator of final height was decreased with surgical treatment alone and combined medroxyprogesterone acetate and spironolactone. Both parameters normalized with cyproterone acetate and testolactone. Height velocity SDS, however, was higher with testolactone (0.97 vs. 0.45).
authors.affiliation: Division of Pediatric Endocrinology, University of Essen, Federal Republic of Germany.
authors.forename: B P
authors.initials: BP
authors.lastname: Hauffa
authors.forename: W
authors.initials: W
authors.lastname: Havers
authors.forename: H
authors.initials: H
authors.lastname: Stolecke
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage; D001827:Body Height / Q000187:drug effects*; D001846:Bone Development / Q000187:drug effects*; D003131:Combined Modality Therapy; D003534:Cyproterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017373:Cyproterone Acetate; D004359:Drug Therapy, Combination; D005260:Female; D005357:Fibrous Dysplasia of Bone / Q000628:therapy*; D005359:Fibrous Dysplasia, Polyostotic / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D010048:Ovarian Cysts / Q000601:surgery / Q000628:therapy*; D010050:Ovarian Function Tests; D013148:Spironolactone / Q000008:administration & dosage; D013738:Testolactone / Q000008:administration & dosage*
chemical_list: D000726:Androgen Antagonists; D013148:Spironolactone; D017373:Cyproterone Acetate; D013738:Testolactone; D017258:Medroxyprogesterone Acetate; D003534:Cyproterone; D008525:Medroxyprogesterone